Archives of rheumatology最新文献

{"title":"Prevalence and characteristics of juvenile fibromyalgia syndrome in pediatric rheumatic diseases: A comparative study.","authors":"Gülcan Özomay Baykal, Duygu Kurtuluş, Serap Ata, Betül Sözeri","doi":"10.46497/ArchRheumatol.2024.10562","DOIUrl":"10.46497/ArchRheumatol.2024.10562","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to evaluate the frequency of juvenile fibromyalgia syndrome (JFMS) in patients diagnosed with juvenile idiopathic arthritis (JIA) and familial Mediterranean fever (FMF) with joint symptoms and compare them with a healthy control group.</p><p><strong>Patients and methods: </strong>This retrospective study was conducted with 181 participants between January and April 2023. One hundred twenty-one patients with JIA or FMF diagnoses (71 females, 50 males; mean age: 15.6±2.1 years; range, 12 to 23 years) and 60 healthy individuals (36 females, 24 males; mean age: 14.5±1.6 years; range, 12 to 17 years) were included in the patient group and the control group, respectively. The pain and symptom assessment scale was applied for the JFMS diagnosis, and the output data were analyzed with the widespread pain index and symptom severity scale.</p><p><strong>Results: </strong>Of the patient group, 57% (n=69) were diagnosed with FMF, and 43% (n=52) were diagnosed with JIA. When the two groups were compared with those diagnosed with JFMS, statistical significance was detected (p<0.05). Thirteen (87%) of those diagnosed with JFMS were female, and two (13%) were male, with a statistically significant difference.</p><p><strong>Conclusion: </strong>In patients with JIA and FMF who complain of chronic musculoskeletal pain, tiredness, and weakness, JFMS diagnosis should always be considered in the clinical evaluation.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"384-392"},"PeriodicalIF":1.1,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unmet needs in psoriatic arthritis, a narrative review.","authors":"Clementina Lopez-Medina, Umut Kalyoncu, Laure Gossec","doi":"10.46497/ArchRheumatol.2024.10710","DOIUrl":"10.46497/ArchRheumatol.2024.10710","url":null,"abstract":"<p><p>Psoriatic arthritis is a chronic rheumatic disease that poses challenges in its diagnosis, evaluation, and management. The heterogeneity in the manifestations and the absence of definitive diagnosis biomarkers often complicates the process of accurate diagnosis. Furthermore, the involvement of multiple disease domains poses difficulties in assessing disease activity and defining the concept of remission. Despite therapeutic advancements, a subset of patients remains refractory to treatment, leading to the emergence of the concept of \"difficult-to-treat\" patients and the necessity for novel therapeutic approaches (e.g., drugs with novel mechanisms of action; combinations of treatments). This review addresses key unmet needs in psoriatic arthritis, in terms of diagnosis, classification, evaluation, comorbidities and treatment.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 2","pages":"159-171"},"PeriodicalIF":1.1,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive risk factors for one-year mortality in idiopathic inflammatory myopathy patients with interstitial lung disease: A retrospective, single-center cohort study.","authors":"Minna Jiang, Xiaohong Wen, Sisi Xia, Yiqun Guo, Yu Bai","doi":"10.46497/ArchRheumatol.2024.10418","DOIUrl":"10.46497/ArchRheumatol.2024.10418","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to analyze the risk factors for mortality of idiopathic inflammatory myopathy (IIM) patients admitted with interstitial lung disease (ILD) to guide rapid and accurate judgment of clinical prognosis.</p><p><strong>Patients and methods: </strong>This retrospective, single-center cohort study was conducted with 135 participants (37 males, 98 females; mean age: 54.8±11.1 years; range, 24 to 85 years) between June 1, 2016, and June 30, 2021. The participants were categorized into the survival group (n=111) and nonsurvivors (n=24) according to whether they survived during the one-year follow-up. The independent risk factors for mortality in one year after discharge were analyzed. Receiver operating characteristic curve analysis was used to determine the accuracy of oxygenation index at baseline combined with pulmonary infection (PI) at follow-up to indicate death in IIM-ILD patients.</p><p><strong>Results: </strong>Compared to the survival group, nonsurvivors were older (p=0.006) and had a higher proportion of anti-MDA5 (melanoma differentiation-associated protein 5) positivity (p<0.001). The ILD duration was shorter (p=0.006), the oxygenation index was lower (p<0.001), and the intensive care unit occupancy rate (p<0.001) and ventilator utilization rate (p<0.001) were elevated in nonsurvivors compared to the survival group. Oxygenation index at baseline (odds ratio [OR]=1.021, 95% confidence interval [CI]: 1.001-1.023, p=0.040) and PI (clinical judgment) at follow-up (OR=16.471, 95% CI: 1.565-173.365, p=0.020) were found as independent risk factors for death in the year after discharge in IIM inpatients with ILD. An oxygenation index ≤279 mmHg at baseline combined with PI at follow-up exhibited a promising predictive value for all-cause death in IIM-ILD patients within one year.</p><p><strong>Conclusion: </strong>Oxygenation index at baseline and PI during follow-up were independent risk factors for death of IIM-ILD patients within one year after discharge. Patients with an oxygenation index ≤279 mmHg at baseline had an increased risk of death once they developed PI during the one-year follow-up.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 2","pages":"213-220"},"PeriodicalIF":1.1,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tertiary adrenal insufficiency in a patient with familial Mediterranean fever: Association or coincidence?","authors":"Nozomi Harai, Shunichiro Hanai, Tadatsugu Hosokawa, Kyoichiro Tsuchiya, Daiki Nakagomi","doi":"10.46497/ArchRheumatol.2024.10400","DOIUrl":"10.46497/ArchRheumatol.2024.10400","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 2","pages":"314-316"},"PeriodicalIF":1.1,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis.","authors":"Tarun Krishna Boppana, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, Randeep Guleria","doi":"10.46497/ArchRheumatol.2024.10199","DOIUrl":"10.46497/ArchRheumatol.2024.10199","url":null,"abstract":"<p><strong>Objectives: </strong>This systematic review and meta-analysis aimed at summarizing the evidence of efficacy and safety of rituximab in rheumatoid arthritis-related interstitial lung disease (RA-ILD).</p><p><strong>Materials and methods: </strong>PubMed and Embase databases were searched until June 22, 2022, to identify studies on RA-ILD treated with rituximab, confined to predefined inclusion and exclusion criteria. A systematic review and meta-analysis were performed on the included studies to assess the overall stabilization or improvement in ILD, changes in percent-predicted (%-predicted) forced vital capacity (FVC), and %-predicted diffusion capacity of lungs for carbon monoxide (DLCO) following rituximab therapy.</p><p><strong>Results: </strong>A total of 15 studies (4 prospective and 11 retrospective studies) were included, with a total of 314 patients. There were 105 (60.7%) females out of 173 subjects for whom sex details were available from seven studies. The overall pooled proportion of patients with stabilization or improvement in ILD was 0.88 [95% confidence interval (CI): 0.76-0.96, p=0.02]. Rituximab improved FVC from baseline by 7.50% (95% CI: 1.35-13.65; p=0.02, fixed effect). Similarly, rituximab improved DLCO by 6.39% (95% CI: 1.366-14.43; p=0.12, random-effect). Two retrospective studies reported reduced mortality with rituximab therapy compared to tumor necrosis factor-alpha inhibitors.</p><p><strong>Conclusion: </strong>Treatment with rituximab in RA-ILD was associated with a significant improvement in %-predicted FVC, as well as stabilization or improvement in ILD after one year of treatment.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 2","pages":"317-329"},"PeriodicalIF":1.1,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The first involved joints and associated factors in patients with rheumatoid arthritis.","authors":"Mete Pekdiker, Hamdi Oğuzman","doi":"10.46497/ArchRheumatol.2024.10417","DOIUrl":"10.46497/ArchRheumatol.2024.10417","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the first involved joints and associated factors in Turkish patients with rheumatoid arthritis (RA).</p><p><strong>Patients and methods: </strong>This retrospective cross-sectional study included 300 newly diagnosed and disease-modifying antirheumatic drug-naïve RA patients (240 females, 60 males; mean age: 54±1.2 years; range, 18 to 82 years). Baseline demographic, clinical, and laboratory data were evaluated between January 2022 and December 2022. The patients were divided into four groups according to autoantibody profile: antibody-negative patients (Group 1; both RF and anti-CCP were negative in this group of patients), RF-positive patients (Group 2), anti-CCP-positive patients (Group 3), and patients with dual seropositivity with RF and antiCCP (Group 4). The patients were also divided into two groups according to the size of the first affected joint: patients with SJI at diagnosis and patients without SJI involvement at diagnosis.</p><p><strong>Results: </strong>Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody positivity rates were 40.3% and 35.6%, respectively. The mean lag time to diagnosis was 25±36 months. At the disease onset, 20% of patients did not have small joint involvement (SJI). Seronegative patients tended to be female (p=0.001), had longer lag time (p=0.001), and had lower levels of C-reactive protein (p=0.025), white blood count (p=0.005), and neutrophil/lymphocyte ratio (p=0.001) compared to the dual seropositive group. Patients presenting with SJI had a younger age (p=0.002), tended to be female (p=0.001), and had lower RF (p=0.034) and anti-CCP (p=0.031) positivity. Only age (p=0.005) and dual seronegativity (RF and anti-CCP; p=0.035) were the independent predictors of SJI in multivariate analysis.</p><p><strong>Conclusion: </strong>The decreasing age and seronegative status were defined as independent risk factors of SJI at the onset of RA. Population-based, prospective studies are needed for earlier diagnosis.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 2","pages":"274-284"},"PeriodicalIF":1.1,"publicationDate":"2024-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196237/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141461285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Could rituximab be a silver lining in refractory bone marrow fibrosis caused by lupus?","authors":"Dilara Bulut Gökten, Fatma Yümün Kavak, Rıdvan Mercan","doi":"10.46497/ArchRheumatol.2024.10564","DOIUrl":"10.46497/ArchRheumatol.2024.10564","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 3","pages":"476-478"},"PeriodicalIF":1.1,"publicationDate":"2024-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11537692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142592322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What does artificial intelligence mean in rheumatology?","authors":"Kunal Chandwar, Durga Prasanna Misra","doi":"10.46497/ArchRheumatol.2024.10664","DOIUrl":"10.46497/ArchRheumatol.2024.10664","url":null,"abstract":"<p><p>Intelligence is the ability of humans to learn from experiences to ascribe conscious weights and unconscious biases to modulate their outputs from given inputs. Transferring this ability to computers is artificial intelligence (AI). The ability of computers to understand data in an intelligent manner is machine learning. When such learning is with images and videos, which involves deeper layers of artificial neural networks, it is described as deep learning. Large language models are the latest development in AI which incorporate self-learning into deep learning through transformers. AI in Rheumatology has immense potential to revolutionize healthcare and research. Machine learning could aid clinical diagnosis and decision-making, and deep learning could extend this to analyze images of radiology or positron emission tomography scans or histopathology images to aid a clinician's diagnosis. Analysis of routinely obtained patient data or continuously collected information from wearables could predict disease flares. Analysis of high-volume genomics, transcriptomics, proteomics, or metabolomics data from patients could help identify novel markers of disease prognosis. AI might identify newer therapeutic targets based on in-silico modelling of omics data. AI could help automate medical administrative work such as inputting information into electronic health records or transcribing clinic notes. AI could help automate patient education and counselling. Beyond the clinic, AI has the potential to aid medical education. The ever-expanding capabilities of AI models bring along with them considerable ethical challenges, particularly related to risks of misuse. Nevertheless, the widespread use of AI in Rheumatology is inevitable and a progress with great potential.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progressive pulmonary fibrosis in patients with connective tissue disease-associated interstitial lung disease: An explorative study.","authors":"Jakob Höppner, Maximilian Wollsching-Strobel, Falk Schumacher, Wolfram Windisch, Melanie Berger","doi":"10.46497/ArchRheumatol.2024.10105","DOIUrl":"10.46497/ArchRheumatol.2024.10105","url":null,"abstract":"<p><strong>Objectives: </strong>The aim of this study was to identify differences and similarities between connective tissue disease (CTD) patients with and without progressive pulmonary fibrosis (PPF) by applying the new guidelines.</p><p><strong>Patients and methods: </strong>Patient characteristics and disease courses from medical records of 50 CTD-associated Interstitial lung disease (ILD) patients (33 females, 17 males; mean age: 60.1±12.9 years) were longitudinally studied between January 2018 and May 2022. Respiratory involvement in CTD patients was described, and differences in CTD patients who developed PPF compared to those who did not were identified by the 2022 ATS (American Thoracic Society)/ERS (European Respiratory Society)/JRS (Japanese Respiratory Society)/ALAT (Asociación Latinoamericana de Thórax) Guidelines on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in Adults.</p><p><strong>Results: </strong>In the majority (74%) of patients, CTD was diagnosed before ILD onset. Nonspecific interstitial pneumonia was the most common high resolution computer tomography pattern, followed by the usual interstitial pneumonia pattern. On pulmonary function test, 38% had a restrictive pattern at baseline. Patients without PPF tended to have worse lung function at baseline and increased macrophage count in bronchoalveolar lavage than patients with PPF.</p><p><strong>Conclusion: </strong>In patients without PPF, disease progression may be missed, resulting in inadequate management. Interdisciplinary management of patients with CTD with the participation of pulmonologists and precise lung function diagnostics is recommended.</p>","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"46-51"},"PeriodicalIF":0.0,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is procalcitonin elevation always an indicator of bacterial infection?","authors":"Volkan Ecesoy, Hilal Ecesoy","doi":"10.46497/ArchRheumatol.2024.9940","DOIUrl":"10.46497/ArchRheumatol.2024.9940","url":null,"abstract":"","PeriodicalId":93884,"journal":{"name":"Archives of rheumatology","volume":"39 1","pages":"133-135"},"PeriodicalIF":0.0,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}